十大网赌正规网址下载(2024官方网站)

Be the most trusted biotech company

2022-03-17

Evolving from Biotech to Biopharma, Mapping out the Future
2022-03-16

Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma
2022-03-01

汉利康Ⓡ Approved by NMPA for New Indication Differentiated Strategy Benefits a Wider Patient Population
2022-02-23

Henlius Entered into a Collaboration with Getz Pharma to Commercialise Adalimumab Biosimilar 汉达远, Covering 11 Emerging Markets in Asia, Africa and Europe
2022-02-14

First Subject Dosed in the Australia Phase 1 Trial of Henlius' Potential First-In-Class Anti PD-L1×TIGIT Bispecific Antibody
2022-01-28

First Subject Dosed of a Phase 2 Study of Henlius’ Novel Anti-PD-1 mAb Serplulimab Combined with Anti-EGFR mAb HLX07 in First-line EGFR High Expression sqNSCLC Patients
2022-01-27

First Patient Dosed in the Phase 2 Clinical Trial in LCH/ECD of Henlius BRAF Inhibitor HLX208
2022-01-20

The preclinical and structural analysis results of Henlius’ innovative anti-PD-1 mAb serplulimab, published in an international journal PLOS ONE
2022-01-18

Accelerating the Innovation Pipeline, Henlius BRAF Inhibitor HLX208 IND for Phase 1b/2 Studies Approved by NMPA

1
...
4
5
6
7